ABBOTT LABORATORIES

(ABT)
  Report
Delayed Nyse  -  04:03 2022-07-05 pm EDT
109.30 USD   -0.83%
07/05Evercore ISI Lowers Abbott Laboratories's Price Target to $116 From $135, Maintains Outperform Rating
MT
06/29Abbott Hosts Conference Call for Second-Quarter Earnings
PR
06/28AbbVie Names Michael President, Reents Finance Chief
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 153 608187 600241 365191 378--
Enterprise Value (EV)1 167 607199 509249 166195 778190 724184 969
P/E ratio 42,2x44,0x35,7x29,6x27,6x24,0x
Yield 1,52%1,40%1,29%1,72%1,85%1,97%
Capitalization / Revenue 4,81x5,42x5,60x4,58x4,65x4,37x
EV / Revenue 5,25x5,76x5,78x4,68x4,63x4,23x
EV / EBITDA 20,5x21,7x19,4x16,6x16,4x14,5x
Price to Book 4,92x5,92x6,93x5,08x4,56x4,09x
Nbr of stocks (in thousands) 1 768 4561 713 4011 714 9681 750 942--
Reference price (USD) 86,9109141109109109
Announcement Date 01/22/202001/27/202101/26/2022---
1 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 31 90434 60843 07541 80241 18043 770
EBITDA1 8 1889 20412 81511 78311 60712 765
Operating profit (EBIT)1 7 1108 00911 32410 32110 21311 234
Operating Margin 22,3%23,1%26,3%24,7%24,8%25,7%
Pre-Tax Profit (EBT)1 4 0774 9688 2117 4027 7569 330
Net income1 3 6874 4717 0716 6607 1307 974
Net margin 11,6%12,9%16,4%15,9%17,3%18,2%
EPS2 2,062,493,943,693,964,55
Dividend per Share2 1,321,531,821,882,022,15
Announcement Date 01/22/202001/27/202101/26/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4
Net sales1 10 92811 46811 89510 3439 5389 912
EBITDA1 3 3693 2634 2472 7782 4312 532
Operating profit (EBIT)1 3 0422 8943 6202 3542 0502 165
Operating Margin 27,8%25,2%30,4%22,8%21,5%21,8%
Pre-Tax Profit (EBT) ------
Net income1 2 1001 9892 4471 4261 2031 315
Net margin 19,2%17,3%20,6%13,8%12,6%13,3%
EPS2 1,171,111,370,790,670,74
Dividend per Share ------
Announcement Date 10/20/202101/26/202204/20/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 13 99911 9097 8014 400--
Net Cash position1 ----6546 409
Leverage (Debt / EBITDA) 1,71x1,29x0,61x0,37x-0,06x-0,50x
Free Cash Flow1 4 4985 7248 6489 3188 8969 578
ROE (Net Profit / Equities) 18,9%20,5%27,3%23,0%21,6%21,4%
Shareholders' equity1 19 54921 79325 88728 96632 99537 177
ROA (Net Profit / Asset) 8,60%9,33%9,57%11,2%9,99%12,5%
Assets1 42 85447 91673 87259 34771 39163 940
Book Value Per Share2 17,618,520,321,524,026,7
Cash Flow per Share2 3,454,425,897,316,306,15
Capex1 1 6382 1771 8851 9111 9502 026
Capex / Sales 5,13%6,29%4,38%4,57%4,74%4,63%
Announcement Date 01/22/202001/27/202101/26/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Key data
Capitalization (USD) 191 377 992 187
Net sales (USD) 43 075 000 000
Number of employees 113 000
Sales / Employee (USD) 381 195
Free-Float 87,5%
Free-Float capitalization (USD) 167 525 273 041
Avg. Exchange 20 sessions (USD) 588 669 470
Average Daily Capital Traded 0,31%
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA